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Background. Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the
response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential
of limiting future therapy options and affecting the efficacy of postexposure prophylaxis.
Methods. We determined the baseline rate of drug resistance in 2208 therapy-naive patients recently and
chronically infected with HIV-1 from 19 European countries during 1996–2002.
Results. In Europe, 1 of 10 antiretroviral-naive patients carried viruses with 1 drug-resistance mutation.
Recently infected patients harbored resistant variants more often than did chronically infected patients (13.5% vs.
8.7%; ). Non-B viruses (30%) less frequently carried resistance mutations than did subtype B virusesPp .006
(4.8% vs. 12.9%; ). Baseline resistance increased over time in newly diagnosed cases of non-B infection: fromP ! .01
2.0% (1/49) in 1996–1998 to 8.2% (16/194) in 2000–2001.
Conclusions. Drug-resistant variants are frequently present in both recently and chronically infected therapy-
naive patients. Drug-resistant variants are most commonly seen in patients infected with subtype B virus, probably
because of longer exposure of these viruses to drugs. However, an increase in baseline resistance in non-B viruses
is observed. These data argue for testing all drug-naive patients and are of relevance when guidelines for management
of postexposure prophylaxis and first-line therapy are updated.
In countries with wide access to antiretroviral therapy,
various drugs are currently available to suppress HIV-
1 infection. Unfortunately, the frequent development
of drug resistance during combination therapy limits
the sustained response to antiretroviral drugs in many
HIV-1–infected patients. Because cross-resistance is com-
mon, failure of therapy can also result in resistance to
drugs that were not a part of the failing regimen. Drug-
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resistance testing of HIV-1 is therefore an important
tool for the selection of subsequent regimens, and it has
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become a standard of care in the clinical management of ther-
apeutic failure [1].
Suggestions have been made that viruses that contain mu-
tations conferring drug resistance may be less transmissible than
drug-sensitive virus [2]. However, over the past few years, trans-
mission of all kinds of drug-resistant HIV-1 variants from ther-
apy-experienced patients to newly infected individuals has been
observed [3]. Recent publications have shown that the acqui-
sition of an infection with drug-resistant HIV-1 may result in
a less-favorable response to therapy [4–6].
Resistance testing before the initiation of therapy may help
guide the optimal selection of antiretroviral drugs. Different
categories of patients can be identified, depending on the du-
ration of infection. For recently infected patients, current guide-
lines recommend drug-resistance testing before the initiation
of therapy [1, 7]. For chronically infected patients, the guide-
lines are less concordant, because it is assumed that, in the ab-
sence of drug-selection pressure, reversion to or overtake by
drug-sensitive virus can occur over time and preclude the de-
tection of drug-resistant variants.
Widespread dissemination of drug-resistant HIV-1 variants
has the serious potential to limit therapeutic options in new
patients. In addition, the efficacy of postexposure prophylaxis
may be affected by the circulation of drug-resistant HIV-1 [8,
9]. To gain insight into the prevalence of transmitted drug re-
sistance in Europe in both categories of therapy-naive patients,
a large study of 2208 therapy-naive HIV-1–infected patients
from 19 European countries was conducted.
PATIENTS, MATERIALS, AND METHODS
Study population. HIV-1–seropositive individuals (18 years
old) were eligible for the study if they had never been exposed
to antiretroviral drugs before the time of sampling. CD4+ cell
counts and HIV RNA loads were determined within 3 months
of the moment of drug-resistance analysis. Antiretroviral-naive
patients were considered to be chronically infected if they were
known to have been infected for 11 year before genotypic analy-
sis was performed. Newly diagnosed cases were considered to
be recent infection when HIV-1 antibody was not detectable by
EIA with subsequent documented HIV-1 seroconversion within
1 year before the drug-resistance analysis was performed. If no
reliable information about the duration of infection was avail-
able, newly diagnosed cases were classified as having an unknown
duration of infection.
Data collection. The Combined Analysis of Resistance
Transmission over Time of Chronically and Acute Infected HIV
Patients (CATCH) study is a substudy of the European Com-
mission–supported scientific surveillance program Strategy to
Control Spread of HIV Drug Resistance (SPREAD), in which
clinical centers and public-health institutes from 27 countries
across Europe participate. The CATCH study was conducted
as a starting point for assessing the current status of baseline
resistance in anticipation of the results of the SPREAD sur-
veillance program. The CATCH study was also open to centers
not currently participating in the SPREAD program. More in-
formation on the participating centers in the CATCH study
and the SPREAD program can be found at http://www.spread
-europe.org. Data from the period 1996–2002 were collected
as part of national surveillance studies designed to investigate
the transmission of drug resistance or of the standard clinical
practice of baseline sequencing for all newly diagnosed cases
in a center. Data were included from the following 19 countries
(no. of patients): Austria (84), Belgium (128), Denmark (116),
Finland (8), France (249), Germany (62), Greece (40), Israel
(104), Italy (365), Luxembourg (161), The Netherlands (25),
Norway (23), Poland (35), Portugal (91), Serbia-Montenegro
(10), Spain (142), Sweden (153), Switzerland (260), and the
United Kingdom (152). Data were retrieved from centers rep-
resenting different geographical parts of each country, with the
exception of Belgium and The Netherlands, where data were
collected from only 1 geographical area. Part of the national
data sets have been published elsewhere [10–16].
Genotypic resistance analysis. Population-based nucleotide
sequence analysis of HIV pol was performed by local labora-
tories. Sequence alignment was performed with Clustal X (ver-
sion 1.81; available at: http://bips.u-strasbg.fr/fr/Documentation
/ClustalX/) [17]. Genotypic resistance was defined as the pres-
ence of 1 resistance-related mutation as specified by the con-
sensus mutation figures of the International AIDS Society–USA
(IAS; May/June 2002 version) [18]. The substitutions at codon
215, which are listed as footnotes in the IAS figures and are
considered to be indicators of transmitted resistance, were in-
cluded in the analysis as well [6]. The minor mutations in
protease and the mutations E44D and V118I in reverse tran-
scriptase (RT) were not taken into account, because it is not
possible to determine whether these mutations result from nat-
ural variation or from exposure to antiretroviral drugs (for a
complete list, see table 2 below).
Sequence quality verification. To assure the quality of the
CATCH data set, each submitted sequence was checked before
inclusion. Sequences that contained stop codons and individual
resistance codons with ambiguities consisting of 12 bases per
nucleotide position or of 12 ambiguities per codon were ex-
cluded from the analysis.
Prediction of susceptibility. Assessment of the possible im-
pact of transmitted drug resistance on the therapeutic response
was performed by use of resistance interpretation algorithms.
For this purpose, the FASTA files of strains carrying drug-re-
sistance mutations were analyzed by use of 2 freely available
algorithms, the Stanford drug-resistance algorithm (beta test
version 3.6; available at: http://hivdb.stanford.edu) and Retro-
Gram (version 1.6; Virology Education; available at: http://
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Table 1. Patient characteristics.
Characteristic All
Chronically
infected
(11 year)
Newly diagnosed
Infection
1 year Unknown
Patients, no. 2208 607 777 824
Age,a mean (SD), years 36 (10) 36 (10) 34 (9) 37 (11)
Sex,b %
Male 73 68 81 70
Female 27 32 19 30
Viral subtype B, no. (%) 1535 (70) 442 (73) 620 (80) 473 (57)
Route of transmission,c %
Homosexual contact 43 32 51 35
Heterosexual contact 41 41 30 54
Injection drug use 15 25 13 10
Other 1 1 6 2
Baseline values
CD4+ cell count,d median (range), cells/mm3 408 (1–1764) 313 (1–1433) 500 (21–1764) 330 (1–1262)
HIV-RNA load,e mean (SD), log copies/mL 4.82 (0.86) 4.65 (0.75) 5.03 (0.94) 4.71 (0.79)
a Data available for 1958 patients.
b Data available for 2195 patients.
c Data available for 1571 patients.
d Data available for 1417 patients.
e Data available for 1856 patients.
www.retrogram.com). The Stanford HIV Database algorithm
assigns a “drug penalty score” for each drug-resistance muta-
tion. The total score for a drug is derived by adding individ-
ual mutation scores and is translated into 5 levels of inferred
drug resistance: susceptible (S), potential low-level resistance
(PLR), low-level resistance (LR), intermediate resistance (IR),
and high-level resistance (HR) [19]. RetroGram is an expert
opinion–based algorithm that predicts the potential clinical ef-
ficacy of antiretroviral drugs [20]. Genotype interpretation by
RetroGram results in a 4-category suitability ranking (A, B, C,
or D). The outcome of the algorithms was converted into the
following levels of susceptibility: susceptible (S and A), low-
level resistance (PLR, LR, and B), intermediate resistance (IR
and C), and high-level resistance (HR and D). Reduced sus-
ceptibility to a drug was scored when one of the systems in-
dicated the presence of any level of resistance. In cases of dis-
cordance, the highest level of resistance was recorded.
Phylogenetic analysis. Subtypes were assessed by the con-
struction of phylogenetic trees by use of the neighbor-joining
method. Pairwise distance matrices were generated by use of
the Kimura 2-parameter distance estimation method with a
transition:transversion ratio of 2.0. The consistency of the phy-
logenetic clustering was tested by bootstrap analysis with 100
replicates. Bootstrap values 170 were considered to be sufficient
for subtype assignment. Trees were based on pol sequences and
were constructed for each country, to exclude cross-contami-
nation between the samples.
Statistical methods. A weighted analysis was performed to
examine whether differences in the number of patients included
per country distorted the prevalence estimates. The weight for
each country was the number of patients living with HIV/AIDS
in 1999 (available from EuroHIV and the Joint United Nations
Programme on HIV/AIDS). For statistical analysis and report-
ing of resistance, the calendar years were stratified into 3 in-
tervals: 1996–1998, 1999–2000, and 2001–2002.
Differences in the percentage of strains that were resistant
for each interval of time were analyzed by means of the x2 test.
Logistic regression was used to study the association between
transmission of resistance and both subtype and duration of
infection. Patients with an unknown duration of infection were
excluded from time-trend analysis.
RESULTS
Study population. We enrolled 2208 HIV-1–infected therapy-
naive patients from whom a blood sample for HIV pol nucle-
otide sequence analysis was available during the period 1996–
2002. Table 1 shows the characteristics of the patients, grouped
according to duration of infection. All patients were naive for
therapy at the time of testing; 1601 were newly diagnosed cases
of HIV infection, and 607 were known to be chronically infect-
ed (11 year). Of the newly diagnosed cases, 777 patients were
identified to have a recent infection (1 year) on the basis of
negative or indeterminate HIV serological results. The remain-
ing newly diagnosed cases (824) presented with an unknown
duration of infection. Transmission routes were identified for
1571 patients. The most common transmission route was sexual
contact, 678 (43%) through sex between men and 641 (41%)
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Table 2. Resistance profiles.
Mutationa
Frequency
in all patients,
no. (%)b
Frequency
in patients
with drug-resistant
HIV, %
Any (NRTI, NNRTI, major PI) 230 (10.4) …
NRTI
Any 165 (7.6) 72.1
1 89 (4.1) 38.9
2 76 (3.5) 33.2
M41L 57 (2.6) 24.9
D67N 33 (1.5) 14.4
K70R 22 (1.0) 9.6
M184I/V 31 (1.4) 13.5
L210W 21 (1.0) 9.2
T215F/Y 34 (1.6) 14.8
T215A/C/D/E/N/S/Vc 59 (2.7) 25.8
K219Q/E 25 (1.1) 10.9
Any TAMd 138 (6.3) 60.3
2 TAMs 72 (3.3) 31.4
Any TAM + M184 V 16 (0.7) 7.0
NNRTI
Any 64 (2.9) 27.8
1 53 (2.4) 23.0
2 11 (0.5) 4.7
K103N 33 (1.5) 14.3
V108I 12 (0.5) 5.2
Y181C 11 (0.5) 4.8
PI
Any 54 (2.5) 23.7
1 44 (2.0) 19.3
2 10 (0.5) 4.4
M46I/L 22 (1.0) 9.6
V82A/F/S/T 12 (0.6) 5.3
L90M 23 (1.1) 10.1
NOTE. NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nu-
cleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine
analogue mutation.
a In addition to the mutations listed in the table (frequency, 10.5%), the
following mutations were observed: A62V, K65R, T69D, L74V, V75A, F77L,
L100I, F116Y, Y188C/H/L, Q151M, G190A/S, P225H, and M230L in RT and
D30N, G48V, and I84V in protease. Not observed were V75I/M/S/T, Y115F,
V106A/M, V108I, Y181I, and P236L in RT and I50L/V in protease.
b No. of samples analyzed for NRTIs, 2177; for NNRTIs, 2190; and for PIs,
2178.
c Frequency of individual mutations at codon 215: A, 2; C, 5; D, 23; E, 1;
N, 4; S, 20; N/S, 1; and V, 3.
d M41L, D67N, K70R, L210W, T215A/C/D/E/F/N/S/V/Y, and K219Q.
through heterosexual contact. Other transmission routes were
intravenous drug use (239 [15%]) and exposure to HIV-in-
fected blood (13 [1%]). At the time of resistance analysis, the
median CD4+ cell count was higher in recently infected pa-
tients (500 cells/mm3) than in patients with chronic infection
(313 cells/mm3) or patients with an unknown duration of in-
fection (330 cells/mm3) ( ). The mean HIV RNA loadP ! .001
was slightly higher in recently infected patients (5.03 log HIV
RNA copies/mL) than in patients with chronic infection (4.65
log HIV RNA copies/mL) or an unknown duration of infection
(4.71 log HIV RNA copies/mL) ( ). The proportion ofP ! .001
recently infected patients varied between countries.
Resistance analysis. The percentage of antiretroviral-naive
patients carrying HIV-1 with 1 resistance-related mutation in
Europe during 1996–2002 was 10.4% (95% confidence interval
[CI], 9.1%–11.7%) (230/2208). The weighted analysis resulted
in a comparable prevalence of 11.1% (95% CI, 9.6%–12.2%).
The rate of transmission of drug resistance in each country varied
from 0% (0/8) in the small data set from Finland to 23% (14/
62) in Germany. Recently infected patients (105/777 [13.5%])
harbored resistant HIV variants more frequently than did pa-
tients with chronic infection or patients with infection of un-
known duration (53/607 [8.7%] and 72/824 [8.7%], respectively)
(odds ratio [OR], 1.6 [95% CI, 1.2–2.3]; ). In the subsetPp .006
of patients for whom information on the route of transmission
was available, we did not find statistically significant differences
in the frequency of resistance (data not shown).
Genotypic profiles and predicted susceptibility. Table 2
shows the frequency of resistance-related mutations. Mutations
associated with thymidine analogues (TAMs) (138/229 [60.3%])
were the most predominant. Among the TAMs, substitutions
at RT codon 215, including those associated with partial re-
version to drug-sensitive virus, were detected most frequently
(93/229 [41%]). The most common nonnucleoside RT inhib-
itor (NNRTI)–related mutation was K103N, and the most com-
mon protease inhibitor (PI)–related mutation was L90M. Re-
sistance to 11 class of drugs was observed in 19% (45/231) of
patients carrying drug-resistant HIV variants, whereas resis-
tance to all 3 classes was seen in only 3.5% (8/226).
The possible impact of transmitted resistance on the sus-
ceptibility to the different antiretroviral drugs was calculat-
ed with 2 resistance interpretation algorithms. The predicted
reduction in susceptibility was quite extensive for the class of
nucleoside RT inhibitors (NRTIs; 18%–65% of all strains har-
boring drug-resistance mutations), was intermediate for NNRTIs
(36% for all), and was less pronounced for the PIs (20%–25%)
(figure 1).
Time trends. For patients with a recent infection, the pres-
ence of1 resistance mutation to any antiretroviral drug varied
among time periods (figure 2). The initial relatively high pro-
portion of resistance to NRTIs decreased significantly over time,
from 13.4% (29/217) in 1996–1998, to 9.8% (44/448) in 1999–
2000, and to 6.3% (6/95) in 2001–2002 ( ). In contrast,Pp .048
NNRTI-related resistance was initially low and displayed a sig-
nificant increase through time, from 2.3% (5/217) in 1996–1998,
to 3.1% (14/454) in 1999–2000, and to 9.2% (8/87) in 2001–
2002 ( ). PI-related resistance remained relatively stablePp .02
over time (2.8%, 4.4%, and 3.2%, respectively; ).Pp .65
Phylogenetic analysis. Phylogenetic analysis revealed that
70% of the patients were infected with subtype B virus (1535/
2208). Thirty-six strains (36/2208 [2%]) could not be deter-
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Figure 1. Predicted susceptibility of all viruses carrying drug-resis-
tance–related mutations. The level of resistance to a specific antiretrovi-
ral drug was calculated on the basis of the genotypic profiles by use of
2 Web-based algorithms. Information on the protease inhibitor (PI) ata-
zanavir is only available in the Stanford algorithm, whereas information
on the boosted PIs (except for lopinavir/rtv) is available only in RetroGram.
mined, because they did not cluster with any known subtype
and were therefore scored as unclassified non-B subtypes.
Among non-B subtype, subtype C was the most prevalent
(221/2208 [10%]), followed by subtype G (96/2208 [4%]) and
CRF02_AG (94/2208 [4%]). The proportion of infections with
non-B subtypes varied among countries, from 0% in Poland
and Germany to 170% in Israel (82/104) and Portugal (69/
91). Patients with an infection of known duration more fre-
quently carried subtype B viruses (915/1431 [64%]) than did
patients with an infection of unknown duration (473/824 [57%])
( ).Pp .002
Interestingly, subtype B viruses displayed a higher frequency
of baseline drug resistance (198/1535 [12.9%]) than did non-
B viruses (32/673 [4.8%]) (OR, 3.0 [95% CI, 2.0–4.4]) (P !
). When the analysis was restricted to the subgroup of.001
recently infected patients, the risk of being infected with a drug-
resistant virus was 4 times higher in subtype B infections (99/
620 [16%]) than in non-B infections (6/157 [3.8%]) (OR, 4.2
[95% CI, 1.9–9.4]; ).P ! .001
A multivariate analysis in the subset of patients with an
infection of known duration showed that the difference in re-
sistance between B and non-B subtypes was not confounded
by time and duration of infection. The ORs of the univariate
and multivariate analysis were 3.8 (95% CI, 2.1–6.7) (P! .001)
and 3.7 (95% CI, 2.0–6.6) ( ), respectively. Neverthe-P ! .001
less, a time-dependent increase in the rate of resistance was
observed in all newly diagnosed cases of non-B infection: from
2.0% (1/49) in 1996–1998, to 3.0% (8/265) in 1999–2000, and
to 8.2% (16/194) in 2000–2001.
DISCUSSION
We studied the rate of transmission of drug-resistant HIV-1
over time in Europe. The results of this international study
showed that 10.4% of patients who had never been exposed to
antiretroviral therapy carried HIV with1 drug-resistance mu-
tation. This rate differs from that in several earlier reports. The
previous studies included relatively small numbers of partici-
pants, were often limited to single countries, and varied widely
in the type of mutations considered or the method used to
determine resistance. As a consequence, the rate of new infec-
tions by drug-resistant HIV has been difficult to estimate on
a continentwide scale [3]. To our knowledge, our study is the
first to have analyzed a large resistance data set with uniform
definitions that has taken into account duration of infection
and variations in subtype.
As in any study of the transmission of resistance, it cannot
be ruled out that patients who are considered to be antiret-
roviral naive might not have been truthful about their lack of
exposure to therapy, which would result in an overestimation
of baseline resistance. However, the prescription procedures in
Europe (which are mainly done by HIV-specialized centers),
reimbursement for therapy by national healthcare programs,
and the high level of insurance coverage do not give reasons
for hiding previous exposure to therapy.
Theoretically, differences in sampling strategy and size of the
data sets could have influenced the results. To minimize sam-
pling biases, no isolated clinical samples were included. All
samples in the study were collected either as part of surveillance,
as part of a standard practice of baseline resistance testing, or,
less frequently, as baseline samples for transmission studies. We
consider the influence of sample sizes of the data sets to be
small, given that a weighted analysis showed that differences
in sample size among countries barely influenced the overall
rate of transmission.
Differences in the duration of infections may be more rel-
evant. We found a significant difference ( ) in the levelPp .006
of baseline resistance between recently infected patients (13.5%)
and patients infected for 11 year (8.7%). The lower prevalence
of resistance in chronic infection is most likely due to a lower
exposure to drug-resistant virus in the past. In addition, the
lower prevalence can be explained by reversion from resistant
variants to sensitive wild-type viruses over time [21]. Interest-
ingly, drug-resistance mutations could still be detected in the
plasma of quite a few chronically infected patients, which in-
dicates that complete reversion does not always occur. Indeed,
recent studies have indicated that drug-resistant viruses can
persist for a couple of years in the plasma of treatment-naive
HIV-infected patients [22, 23].
Differences in data sets among countries may also have re-
sulted from specific biological and cultural characteristics as
they relate to national epidemics, such as transmission routes,
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the proportion of non-B viruses, and prescription guidelines.
For instance, the proportion of non-B subtypes seems to have
a substantial influence on the frequency of baseline resistance.
Resistance was higher in antiretroviral-naive patients who were
infected with subtype B (12.9%) than in those infected with
non-B viruses (4.8%). Moreover, in recently infected patients,
the risk of being infected with drug-resistant HIV was 4 times
higher in patients with subtype B infections (16%) than in
patients with non-B infections (4%).
Subtype B was originally the predominant subtype in Europe
and in North America, whereas non-B subtypes have spread
widely in Africa and Asia. Differences in the prevalence of base-
line resistance may thus likely reflect the longer period during
which subtype B viruses have been exposed to antiretroviral
drugs. Interestingly, we noticed a consistent increase in baseline
resistance in non-B viruses. This trend is consistent with the
increasing number of patients identified with non-B viruses in
Europe who are currently being exposed to therapy [14, 24].
The most commonly observed mutations in our study were
those associated with resistance to the thymidine analogues zi-
dovudine and stavudine. Zidovudine and, to a lesser degree,
stavudine have been extensively used as monotherapy or as part
of dual therapy in the past and are frequently present in current
regimens. Also, viruses with TAM resistance profiles may have
better transmissibility and/or preservation in a drug-free en-
vironment, compared with viruses that contain other resistance
mutations that more extensively compromise viral fitness.
The total number of recently infected patients with drug
resistance displayed a fluctuating pattern over time (figure 2).
This pattern results from changes in resistance to RT inhibitors
and can be explained by several mechanisms. The initial high
level of NRTI resistance most likely reflects less-effective viral
suppression and the easy selection of drug resistance at the time
of prescription of suboptimal monotherapy and dual NRTI
therapy. The second phase reflects a decline in NRTI resistance
after the introduction of highly active antiretroviral therapy
(HAART), which results in a more-effective suppression of HIV
replication. Because a low viral load has been associated with
a reduced risk of sexual transmission [25], the introduction of
HAART may account for the observed decrease in transmitted
NRTI drug resistance.
The third phase, which is characterized by a sharp increase
in NNRTI resistance, may reflect the enhanced use of NNRTI-
based regimens, compared with PI-based regimens. An addi-
tional explanation may be a higher level of NNRTI resistance
in the general population, given that NNRTIs have a lower
genetic barrier to resistance and that just one point mutation
can be sufficient to confer high-level resistance to this class of
drugs [26]. In addition, viruses with NNRTI resistance may be
more fit and therefore more able to establish infection in the
new host, compared with PI resistance–related variants.
Our results may have important consequences for clinical
management. The continuous transmission of drug-resistant
viruses to newly infected patients demonstrates that a portion
of HIV-infected individuals receiving antiretroviral medication
is still engaging in risk-related behavior, despite awareness of
their infection status [27]. These patients are receiving medical
attention and should therefore be accessible targets for pre-
vention programs.
Likewise, major concerns exist about the clinical impact of
transmitted drug resistance. In the present data set, the loss in
predicted susceptibility was most extensive for NRTIs, whereas
predicted high-level resistance was more pronounced for drugs
with a low genetic barrier, such as lamivudine and NNRTIs.
The precise impact of transmitted resistance might be difficult
to assess, because the correlation between baseline resistance
and therapeutic response is influenced by the knowledge of
baseline resistance patterns at time of the initiation of therapy
and by the availability of alternative treatment options. Nev-
ertheless, preliminary data show that baseline resistance may
compromise the response to antiretroviral therapy. In 3 stud-
ies, the time to viral suppression was significantly prolonged
in individuals infected with drug-resistant HIV [4, 5, 28]. Also,
the time to virological failure was shorter if baseline resistance
was present [5]. Additionally, individuals from the ICONA co-
hort harboring revertants or atypical mutants at position 215
of RT had an increased risk for selecting drug-resistance mu-
tations and experiencing virological failure [6].
Recently updated guidelines recommend drug-susceptibility
testing for patients presenting with recent infection (!1 year) and
for all newly diagnosed cases when the regional prevalence in an
area increases to 15% and 110%, respectively [1, 7]. Moreover,
the results of modeling studies have suggested that offering ge-
notypic resistance testing before the initiation of therapy was
cost-effective in a US healthcare setting at a 4% prevalence of
baseline resistance [29]. At present, most clinical centers in Eu-
rope do not perform baseline resistance testing as standard pro-
cedure. However, we have shown that considerable baseline drug
resistance can be found in antiretroviral-naive patients even after
they have been infected for 11 year. Therefore, our data support
genotypic resistance testing for all antiretroviral-naive individuals
before combination therapy is selected.
Additionally, when making decisions about initial therapy,
one should consider the possibility that more-complex patterns
are transmitted but that certain mutations are not frequently
identified in antiretroviral-naive patients because of reversion
and the resistance test’s inability to detect minority variants.
In the case of an inadequate virological response to initial ther-
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apy, resistance testing should be repeated early, to identify the
rapid selection of former minority variants.
Finally, the resistance patterns observed in the present study
represent the viruses that are currently circulating in Europe.
Because the failure of postexposure prophylaxis has been de-
scribed after exposure to drug-resistant HIV-1, the reduced
susceptibility of these viruses should be taken into account
when selecting prophylaxis for those patients for whom no
source-related information is available [8, 9, 30].
In conclusion, in 1 of 10 antiretroviral-naive patients in Eu-
rope, viruses with resistance to at least 1 drug are found. This
high prevalence should be taken into account when decisions
are made about initial regimens for therapy-naive individuals
and about the selection of drugs for prophylaxis. Continuous
surveillance of the spread of drug-resistant HIV-1, as well as
the distribution of non-B viruses, is of utmost importance.
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